M. Prince

发表

Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma

H. Prince, M. Prince, 2009 .

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma

S. Fox, S. Lade, E. Thompson, 2018, Oncotarget.

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.

R. Fisher, R. Hicks, M. MacManus, 2002, The American journal of medicine.

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma

S. Fox, S. Lade, E. Thompson, 2018, Oncotarget.

Detection of clinically relevant early genomic lesions in B‐cell malignancies from circulating tumour DNA using a single hybridisation‐based next generation sequencing assay

Daniel L. Cameron, D. Cameron, A. Papenfuss, 2018, British journal of haematology.

TUBULOINTERSTITIAL NEPHRITIS FOLLOWING HIGH‐DOSE IFOSFAMIDE IN THREE BREAST CANCER PATIENTS

D. Power, M. Prince, Prudence A. H ill, 2000, Pathology.

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

U. Wehkamp, R. Cowan, O. Akilov, 2019, The British journal of dermatology.

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

D. Zannino, J. Seymour, C. Sardjono, 2014 .

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.

Jeffrey W. Scott, K. Bhalla, D. DeAngelo, 2007 .

Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL).

S. Bates, R. Piekarz, M. Demierre, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma

M. Beksac, P. Richardson, G. Finn, 2021, Blood cancer journal.

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

M. Dimopoulos, A. Chanan-Khan, A. Belch, 2006 .

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

T. Kuzel, L. Ottesen, N. Dang, 2014 .

High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial

K. Yuen, R. Johnstone, S. Harrison, 2008 .

myeloma reveals an adverse prognostic impact of advanced age A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple

J. Biagi, J. Zeldis, J. Seymour, 2013 .

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin’s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy

R. Hicks, J. Seymour, D. Westerman, 2008, Haematologica.

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Elaine S. Jaffe, Steven L. Allen, Sonali M. Smith, 2008 .

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

A. Belch, J. Zeldis, D. Weber, 2006 .

Gene transfer: A review of methods and applications

M. Prince, Miles H. Prince, 1998, Pathology.

Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers

M. Turner, R. Piekarz, R. Frye, 2009 .

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

D. Hazuda, S. Lewin, R. Sékaly, 2014, PLoS pathogens.

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

S. Iida, M. Guckert, A. Oriol, 2016 .

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer

J. Trapani, R. Johnstone, P. Darcy, 2016, Oncotarget.

A systematic review on the management of pruritus in patients with cutaneous T-cell lymphoma

S. Lazarakis, C. McCormack, O. Buelens, 2021 .

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

M. Dimopoulos, A. Belch, J. S. San Miguel, 2009, European journal of haematology.

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Jerome B. Zeldis, M. Dimopoulos, J. Zeldis, 2005 .

ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma.

H. Einsele, S. Lonial, M. Mohty, 2022, Transplantation and cellular therapy.

Role of radiotherapy in solitary bone plasmacytomas

P. Gibbs, J. Kiffer, G. Quong, 2005 .

Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).

Michael L. Wang, A. Chanan-Khan, A. Belch, 2006 .

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

S. Opat, C. Cheah, D. Talaulikar, 2022, Leukemia & Lymphoma.

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

J. Leonard, S. Bates, L. Hutchins, 2008 .

Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma

S. Harrison, D. Godfrey, N. Gherardin, 2016, Journal of Translational Medicine.

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

A. Chaudhry, J. Brouwer-Visser, M. Ufkin, 2020 .

The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function

Michael L. Wang, M. Dimopoulos, D. Weber, 2008 .

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

M. Keegan, J. Seymour, D. Ritchie, 2007 .

First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).

A. Roberts, K. Bradstock, A. Spencer, 2006 .

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

S. Bates, M. Turner, J. Wright, 2005 .

Efficacy of Single-Agent Bortezomib Versus Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma: A Systematic Review.

M. Adena, M. Prince, J. Hertel, 2005 .

Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL)

W. Sterry, Ann G. Martin, A. Negro-Vilar, 2007 .

The use of experimental murine models to assess novel agents of hematopoietic stem and progenitor cell mobilization.

J. Lévesque, D. Haylock, H. Prince, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011

J. Szer, S. Kirsa, I. Davis, 2011, Internal medicine journal.

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

A. Oriol, P. Moreau, E. Ocio, 2021, Blood.

Brentuximab vedotin in T-cell lymphoma

J. Whisstock, H. Prince, M. Dickinson, 2019, Expert review of hematology.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

S. Iida, A. Oriol, P. Moreau, 2017 .

Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.

R. Twigger, M. Prince, N. Hawkins, 2021, European Journal of Cancer.

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.

P. Goss, M. Crump, M. Prince, 1996, Journal of Clinical Oncology.

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

S. Lonial, S. Bates, S. Whittaker, 2009 .

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

T. Fojo, S. Bates, M. Turner, 2006 .

Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)

P. Zinzani, F. Vanaclocha, M. Duvic, 2008 .

LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

P. Atadja, L. Ellis, R. Johnstone, 2006 .

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.

K. Bhalla, J. Cortes, D. DeAngelo, 2009 .